Serum thyrotrophin has been measured before and after the intravenous administration of 
Introduction
The ability of an intravenous injection of synthetic thyrotrophin releasing hormone (TRH) to stimulate release of thyrotrophin (TSH) from the anterior pituitary is widely recognized as a useful test both to assess the integrity of the hypothalamic-pituitary axis (Jackson, 1982) and to confirm a diagnosis of thyrotoxicosis (Hall et al., 1980; Stitch, 1980) . Thus patients with thyrotoxicosis are distinguished by a failure of serum TSH to rise by > 2 mU/1 within 20 minutes of the intravenous injection of 200 lg TRH (Hall et al., 1980; Stitch, 1980) . There is a strong association between diabetes and thyroid disorders with clin-ical and subclinical autoimmune thyroid disease common in diabetic populations (Gray & Clarke, 1978; Feely & Isles, 1979; Gray et al., 1981) . Antibodies to the anterior pituitary gland have been detected in Type I (insulin-dependent) diabetes (Bottazo et al., 1975) and a relationship between poor diabetic control and impaired TSH secretion has been observed in Type II (non-insulin-dependent) diabetes (Kabadi, 1984) , and it is possible that dynamic pituitary hormonal responses may be blunted in diabetes. We have therefore measured the TSH response to TRH injection, in patients with both clinical types of diabetes, in an attempt to determine whether subclinical pituitary dysfunction is common in diabetes and whether there is a relationship between TSH secretion and diabetic glycaemic control.
Materials and methods
Thirty-three diabetic patients and 58 controls were tested; the clinical features are summarized in Table I measured with a two-site immunoradiometric assay based on two different polyclonal antisera, and standardized against MRC 68/38. The TSH assay performed with a mean interassay precision of > 10% CV and its sensitivity was 0.5 mU/l. Patients whose TSH concentrations were below the sensitivity of the assay were assigned a value of 0.1 mU/l for computational purposes. HbAI was measured by agar gel electrophoresis (Glytrac, Coming). The total integrated TSH concentrations during the 60 minute period following TRH injection were estimated by the trapezoidal rule (Thomas & Finney, 1979) . The area under the curve (0 TSH) was expressed as mU.h.l-'. Statistical analysis utilized Fisher's exact probability test, the Wilcoxon rank sum test and Spearman's rank order correlation coefficient.
Results
Serum T4, T3, basal TSH and prolactin concentrations were within our normal laboratory reference ranges in all 91 subjects. During the TRH tests only 1 of 58 controls failed to achieve an incremental rise (A) of TSH above pre-injection concentration of > 2 mU/I (Table I ) while 7 of the 33 diabetics also failed to respond (P = 0.006). When the diabetic patients were divided into Type I and Type II, only Type II patients showed a statistically significant failure to respond compared to the controls: thus 5 of 13 (P = 0.001) showed inadequate TSH responses while 2 of20 Type I patients failed to respond (P = 0.29). The actual responses ofTSH are shown in Figure 1 . At 30 minutes following TRH the Type II diabetics had significantly lower (P <0.05) TSH concentrations (mean ± s.d. 6.0 ± 5.8) compared with the controls (9.7 ± 5.5). Table II shows the A TSH and 0 TSH in controls and diabetic patients. This shows the similarity ofresponse of TSH in controls and Type I patients but a significantly impaired response in the Type II subjects. While the basal TSH concentrations, A TSH and o TSH were slightly greater in females, there were no significant differences in these TSH values between the sexes in either controls or patients. No association with retinopathy was noted: 3 of the 7 TSH nonresponders had retinopathy while 4 of 26 responders had retinopathy (P = 0.25). Of the subjects who failed to demonstrate a TSH response only one Type I male patient had thyroid microsomal antibodies detectable in a titre of 1/1600.
Overall we found no significant correlation of HbAl with either A TSH (r = 0.01) or 0 TSH (r = 0.09). When the diabetics were divided by sex or type of diabetes no significant correlations with glycaemic control were found. In males, significant correlations were noted between age and both A TSH (r = -0.59, P < 0.02) and 0 TSH (r = -0.55, P < 0.05), while no such associations were noted in females (r = -0.22; with other recognized causes ofimpaired TRH evoked TSH secretion such as hypopituitarism, acromegaly, ophthalmic Grave's disease, autonomous thyroid nodule, multinodular goitre, and certain drugs (Hall et al., 1980; Stitch, 1980) . Thyroid autoimmunity is no more common in Type II diabetic patients than in a matched control group (Kasim & Bessman, 1984) and it seems unlikely that the depressed TSH secretion could have an autoimmune basis. Earlier workers (Ormiston et al., 1971) , as in the present study, have reported impaired TSH release in an occasional normal subject and the reasons for this are not known. Kabadi (1984) has shown a negative association of HbAlc levels and TSH responses in males with Type II diabetics and that the impaired TSH responses could be normalized on improvement of glycaemic control. We have not found such an association and our study suggests that factors other than poor glycaemic control must be important: some ofour patients with Type I diabetes were also poorly controlled, as judged by their high mean HbA1 concentrations, yet they had normal TSH (and prolactin) responses. Others have noted normal TSH responses in Type I diabetes (Morley et al., 1978; Harrower, 1980; Leroith et al., 1980; Dasmahapatra et al., 1981; MacFarlane et al., 1982; Salardi et al., 1984) and that improvement of glycaemic control did not alter the TSH responses to TRH (MacFarlane et al., 1982) . Despite the occasional presence of antibodies to anterior pituitary cells in Type I diabetes (Bottazzo et al., 1975) , dynamic biochemical alterations in thyrotroph and lactotroph function do not seem to occur. In conclusion we feel that Type II diabetes mellitus should be added to the present list of conditions in which diminished TRH evoked TSH secretion may occur. 
